MicroRNA Regulation of Phospholipid Homeostasis in Alzheimer's Disease Pathogenesis

MicroRNA 对阿尔茨海默病发病机制中磷脂稳态的调节

基本信息

  • 批准号:
    10368318
  • 负责人:
  • 金额:
    --
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-07-01 至 2025-12-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY APOE4 is the strongest genetic risk factor for sporadic AD with Ab-dependent and Ab-independent effects on disease pathogenesis. However, the molecular mechanisms underlying the pathogenic nature of APOE4 in AD are not fully elucidated. In previous funding period (07/01/2017-present), we have made significant progress toward understanding micro-RNA (miRNA) regulation of APOE4-induced brain phospholipid dysregulation in AD. We have uncovered a novel regulatory mechanism of miR-195 targeted at APOE4-associated cognitive deficits and lysosomal defects in AD. Notably, we identified miR-195 as a top miRNA candidate involved in the APOE- regulated brain phosphoinositol biphosphate (PIP2) pathway using human ROSMAP and mouse microarray data. Levels of miR-195 are significantly lower in APOE4+ human and mouse brains, and in human inducible pluripotent stem cells (iPSC)-derived neurons and astrocytes when compared to APOE4- counterparts. Over- expressing miR-195 reduces expression levels of its top target synaptojanin 1 (synj1), the brain PIP2 degrading enzyme. Elevating miR-195 ameliorates cognitive deficits and AD pathology in APOE4+ mice and rescues lysosomal defects in APOE4+ iPSC brain cells. Furthermore, our preliminary results support the role of miR-195 as an anti-inflammatory miRNA in regulating microglial function. Our single cell (sc)-RNA seq. analysis of E4FAD mouse brains with miR-195 over-expression suggests that miR-195 alters molecular signatures of microglia sub- clusters. APOE4+ microglia with lower miR-195 levels and higher synj1 expression at baseline, manifests with impaired phagocytic activities and lysosomal defects when compared to APOE3+ microglia. Down-regulation of synj1 or over-expression of miR-195 can rescue these phenotypes. Beside synj1, inflammatory genes pdcd4 and smad7 are predicted targets of miR-195 as well. Over-expression of miR-195 in microglia inhibits lipopolysaccharide (LPS)-induced increases in smad7 and pdcd4 expression, attenuates LPS-induced proinflammatory cytokine release and augments anti-inflammatory responses. In addition, exosomes derived from APOE4/4 astrocytes (ADEs) contain less miR-195 than those in APOE3/3 ADEs, and over-expression of miR-195 in APOE4/4 astrocytes increases miR-195 levels in ADEs which can attenuate LPS-induced pro- inflammatory cytokine release. Therefore, we hypothesize that miR-195 may exhibit anti-inflammatory effects through down-regulation of microglial synj1 to regulate lysosomal function, direct target at microglial inflammatory gene expression and responses, and modulation of neuro-inflammation and tau spread by exosomal miR-195. We propose to characterize the regulation of microglial function by miR-195 during AD pathogenesis in this renewal application. We will: 1) determine the impact of miR-195 on microglia function and APOE-regulated neuro-inflammation in AD in vivo (Aim 1) using cuprizone (CPZ)-induced inflammation in male and female EFAD mouse models (human ApoE4 knock-in at 5xFAD background); 2) to characterize the molecular mechanisms by which miR-195 regulates AD-associated neuro-inflammation (Aim 2) using microglial culture and 3-D co-culture system of mouse brain cells from EFAD and APOE KI mice, as well as from synj1-/-, APOE-/- and TREM2-/- mice (with manipulations of miR-195 levels); 3) to perform high resolution multiscale network modeling using scRNA- seq dataset from mouse brains (Aim 1) and RNA-seq and miR-seq datasets from microglia and 3-D co-culture system (Aim 2) to identify microglia-specific molecular signatures driven by miR-195; and 4) to validate identified microglial signature driven by miR-195 in postmortem human brain samples and investigate their correlation with the development of AD-associated neuro-inflammation during disease progression (Aim 2). The goals of this application aim to elucidate novel pathways and molecular signatures driven by miR-195 protective against APOE4-induced microglial dysfunction in AD pathogenesis, which will facilitate identification and development of a more personalized targeted therapeutic approach to AD-associated neuro-inflammation.
项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Dongming Cai其他文献

Dongming Cai的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Dongming Cai', 18)}}的其他基金

Novel Disease-modifying Small Molecules for Treatment of Alzheimer's Disease”
用于治疗阿尔茨海默病的新型疾病修饰小分子 –
  • 批准号:
    10485602
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Research Infrastructure for the study of Alzheimer's Disease and Alzheimer's Disease-related dementias in older Asian Americans
研究老年亚裔美国人阿尔茨海默病和阿尔茨海默病相关痴呆症的研究基础设施
  • 批准号:
    10730082
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Transcriptional Control of Neuroinflammation in Alzheimer's Disease
阿尔茨海默病神经炎症的转录控制
  • 批准号:
    10574605
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
Dissect the interplay between sex and APOE at the single cell level to uncover novel pathways, targets and therapeutics for Alzheimer's disease
在单细胞水平上剖析性别与 APOE 之间的相互作用,以揭示阿尔茨海默病的新途径、靶点和治疗方法
  • 批准号:
    10300781
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
Transcriptional Control of Neuroinflammation in Alzheimer's Disease
阿尔茨海默病神经炎症的转录控制
  • 批准号:
    10213328
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
Novel small molecules targeting brain phospholipid dysregulation in AD
针对 AD 脑磷脂失调的新型小分子
  • 批准号:
    10457810
  • 财政年份:
    2017
  • 资助金额:
    --
  • 项目类别:
MicroRNA Regulation of Phospholipid Homeostasis in Alzheimer's Disease Pathogenesis
MicroRNA 对阿尔茨海默病发病机制中磷脂稳态的调节
  • 批准号:
    10521283
  • 财政年份:
    2017
  • 资助金额:
    --
  • 项目类别:
Characterization of ApoE4 Induced Phospholipid Dysregulation in AD Pathogenesis
AD 发病机制中 ApoE4 诱导的磷脂失调的特征
  • 批准号:
    8796983
  • 财政年份:
    2015
  • 资助金额:
    --
  • 项目类别:
Characterization of ApoE4 Induced Phospholipid Dysregulation in AD Pathogenesis
AD 发病机制中 ApoE4 诱导的磷脂失调的特征
  • 批准号:
    9086179
  • 财政年份:
    2015
  • 资助金额:
    --
  • 项目类别:
Development of Novel Therapies for AD Targeting Abeta Clearance
针对 Abeta 清除的 AD 新型疗法的开发
  • 批准号:
    8820188
  • 财政年份:
    2014
  • 资助金额:
    --
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了